ArticleNPJ Regenerative medicine2025
Long-term evaluation of human iPSC-derived cartilage for repairing chondral defects.
Article in NPJ Regenerative medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The regulatory significance of chondrocyte hypertrophy in maintaining chondrocyte homeostasis, regeneration and repair.Future science OA · 2026Review
- Cellular Products with Anti-Inflammatory Properties for the Treatment of Cartilage Lesions.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Induced pluripotent stem cells (iPSCs) have demonstrated superior capacity to regenerate hyaline cartilage compared to mesenchymal stromal cells (MSCs). However, most previous animal studies have only conducted short-term assessments. We performed a long-term (8 weeks) in vitro chondrogenesis of human iPSC-derived multipotent progenitor cells (iMPCs) and human MSCs. The expression levels of hypertrophy-related genes were significantly lower in the iMPC group compared to the MSC group, such as collagen type X being 5-fold lower on day 56. In the animal study, implants from the iMPC group maintained more matrix than the MSC group at both short and long-term time points (12 and 48 weeks). Importantly, at 48 weeks, the native cartilage surrounding the defect areas in some rats from the MSC group showed severe degradation, which was not observed in the iMPC group. In conclusion, iMPCs represent a safe and effective cell source for long-term hyaline cartilage repair.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.